In vitro effects of CpG oligodeoxynucleotides delivered by gelatin nanoparticles on canine peripheral blood mononuclear cells of atopic and healthy dogs - a pilot study

Veterinary Dermatology

Volumn 24, Issue 5, 2013, Pages

  Prélaud, Ana Rostaher ^a,b   Fuchs, Sebastian ^b   Weber, Karin ^b   Winter, Gerhard ^b   Coester, Conrad ^b   Mueller, Ralf S ^b  

^a VETSUISSE FACULTY UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA; CANIS FAMILIARIS; DERMATOPHAGOIDES; PYROGLYPHIDAE;

GELATIN; NANOPARTICLE; OLIGODEOXYRIBONUCLEOTIDE;

ANIMAL; ANIMAL DISEASE; ARTICLE; ATOPIC DERMATITIS; CELL CULTURE; CHEMISTRY; CPG ISLAND; DOG; DOG DISEASE; DRUG EFFECT; FEMALE; IMMUNOLOGY; MALE; MONONUCLEAR CELL; PILOT STUDY;

ANIMALS; CELLS, CULTURED; CPG ISLANDS; DERMATITIS, ATOPIC; DOG DISEASES; DOGS; FEMALE; GELATIN; LEUKOCYTES, MONONUCLEAR; MALE; NANOPARTICLES; OLIGODEOXYRIBONUCLEOTIDES; PILOT PROJECTS;

EID: 84883750977     PISSN: 09594493     EISSN: 13653164     Source Type: Journal    
DOI: 10.1111/vde.12056     Document Type: Article

References (56)

1. Olivry T, Sousa CA. The ACVD task force on canine atopic dermatitis (XIX): general principles of therapy. Vet Immunol Immunopathol 2001; 81: 311-316.
2. Marsella R, Girolomoni G. Canine models of atopic dermatitis: a useful tool with untapped potential. J Invest Dermatol 2009; 129: 2351-2357.
3. Marsella R, Sousa CA, Gonzales AJ et al. Current understanding of the pathophysiologic mechanisms of canine atopic dermatitis. J Am Vet Med Assoc 2012; 241: 194-207.
4. DeBoer DJ, Marsella R. The ACVD task force on canine atopic dermatitis (XII): the relationship of cutaneous infections to the pathogenesis and clinical course of canine atopic dermatitis. Vet Immunol Immunopathol 2001; 81: 239-249.
5. Bieber T. Atopic dermatitis. Ann Dermatol 2010; 22: 125-137.
6. Löewenstein C, Mueller RS. A review of allergen-specific immunotherapy in human and veterinary medicine. Vet Dermatol 2009; 20: 84-98.
7. Olivry T, DeBoer D, Favrot C et al. Treatment of canine atopic dermatitis: 2010 clinical practice guidelines from the international task force on canine atopic dermatitis. Vet Dermatol 2010; 21: 233-248.
8. Kanzler H, Barrat FJ, Hessel EM et al. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007; 13: 552-559.
9. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006; 5: 471-484.
10. Hornung V, Rothenfusser S, Britsch S et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002; 168: 4531-4537.
11. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5: 987-995.
12. Marshall JD, Fearon K, Abbate C et al. Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions. J Leukoc Biol 2003; 73: 781-792.
13. Hashimoto M, Asahina Y, Sano J et al. Cloning of canine toll-like receptor 9 and its expression in dog tissues. Vet Immunol Immunopathol 2005; 106: 159-163.
14. House AK, Binns MM, Gregory SP et al. Analysis of NOD1, NOD2, TLR1, TLR2, TLR4, TLR5, TLR6 and TLR9 genes in anal furunculosis of German shepherd dogs. Tissue Antigens 2009; 73: 250-254.
15. Rankin R, Pontarollo R, Ioannou X et al. CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Antisense Nucleic Acid Drug Dev 2001; 11: 333-340.
16. Vollmer J, Weeratna R, Payette P et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 2004; 34: 251-262.
17. Krieg AM, Yi AK, Matson S et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374: 546-549.
18. Mutwiri G, Pontarollo R, Babiuk S et al. Biological activity of immunostimulatory CpG DNA motifs in domestic animals. Vet Immunol Immunopathol 2003; 91: 89-103.
19. Jakob T, Walker PS, Krieg AM et al. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol 1998; 161: 3042-3049.
20. Lipford GB, Sparwasser T, Bauer M et al. Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines. Eur J Immunol 1997; 27: 3420-3426.
21. Sun S, Zhang X, Tough DF et al. Type I interferon-mediated stimulation of T cells by CpG DNA. J Exp Med 1998; 188: 2335-2342.
22. Krieg A. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002; 20: 709-760.
23. Angel JB, Cooper CL, Clinch J et al. CpG increases vaccine antigen-specific cell-mediated immunity when administered with hepatitis B vaccine in HIV infection. J Immune Based Ther Vaccines 2008; 6: 4.
24. Kurata K, Iwata A, Masuda K et al. Identification of CpG oligodeoxynucleotide sequences that induce IFN-gamma production in canine peripheral blood mononuclear cells. Vet Immunol Immunopathol 2004; 102: 441-450.
25. Wernette CM, Smith BF, Barksdale ZL et al. CpG oligodeoxynucleotides stimulate canine and feline immune cell proliferation. Vet Immunol Immunopathol 2002; 84: 223-236.
26. Mueller RS, Veir J, Fieseler KV et al. Use of immunostimulatory liposome-nucleic acid complexes in allergen-specific immunotherapy of dogs with refractory atopic dermatitis - a pilot study. Vet Dermatol 2005; 16: 61-68.
27. Jassies-Vanderlee A, Rutten V, Hessel E et al. Immunostimulatory oligonucleotides modulate canine peripheral blood mononuclear cell activity in vitro. Vet Dermatol 2007; 18(Suppl 1): 386 (abstract).
28. Im Hof M, Williamson L, Summerfield A et al. Effect of synthetic agonists of toll-like receptor 9 on canine lymphocyte proliferation and cytokine production in vitro. Vet Immunol Immunopathol 2008; 124: 120-131.
29. Reinero CR, Cohn LA, Delgado C et al. Adjuvanted rush immunotherapy using CpG oligodeoxynucleotides in experimental feline allergic asthma. Vet Immunol Immunopathol 2008; 121: 241-250.
30. Simons FE, Shikishima Y, Van Nest G et al. Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J Allergy Clin Immunol 2004; 113: 1144-1151.
31. Keppel KE, Campbell KL, Zuckermann FA et al. Quantitation of canine regulatory T cell populations, serum interleukin-10 and allergen-specific IgE concentrations in healthy control dogs and canine atopic dermatitis patients receiving allergen-specific immunotherapy. Vet Immunol Immunopathol 2008; 123: 337-344.
32. Shida M, Kadoya M, Park SJ et al. Allergen-specific immunotherapy induces Th1 shift in dogs with atopic dermatitis. Vet Immunol Immunopathol 2004; 102: 19-31.
33. Creticos PS, Schroeder JT, Hamilton RG et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006; 355: 1445-1455.
34. Senti G, Johansen P, Haug S et al. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Clin Exp Allergy 2009; 39: 562-570.
35. Klinman DM. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 2003; 2: 305-315.
36. Klinman DM, Klaschik S, Sato T et al. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases. Adv Drug Deliv Rev 2009; 61: 248-255.
37. Zwiorek K, Bourquin C, Battiany J et al. Delivery by cationic gelatin nanoparticles strongly increases the immunostimulatory effects of CpG oligonucleotides. Pharm Res 2008; 25: 551-562.
38. Singh M, Ott G, Kazzaz J et al. Cationic microparticles are an effective delivery system for immune stimulatory cpG DNA. Pharm Res 2001; 18: 1476-1479.
39. Coester C, Nayyar P, Samuel J. In vitro uptake of gelatin nanoparticles by murine dendritic cells and their intracellular localisation. Eur J Pharm Biopharm 2006; 62: 306-314.
40. Torchilin VP. Micellar nanocarriers: pharmaceutical perspectives. Pharm Res 2007; 24: 1-16.
41. Klier J, Fuchs S, May A et al. A nebulized gelatin nanoparticle-based CpG formulation is effective in immunotherapy of allergic horses. Pharm Res 2012; 29: 1650-1657.
42. Favrot C, Steffan J, Seewald W et al. A prospective study on the clinical features of chronic canine atopic dermatitis and its diagnosis. Vet Dermatol 2010; 21: 23-31.
43. Coester CJ, Langer K, van Briesen H et al. Gelatin nanoparticles by two step desolvation - a new preparation method, surface modifications and cell uptake. J Microencapsul 2000; 17: 187-193.
44. Zwiorek K, Kloeckner J, Wagner E et al. Gelatin nanoparticles as a new and simple gene delivery system. J Pharm Pharm Sci 2005; 7: 22-28.
45. Stehle ME, Hanczaruk M, Schwarz SC et al. Effects of polyunsaturated fatty acids on isolated canine peripheral blood mononuclear cells and cytokine expression (IL-4, IFN-gamma, TGF-beta) in healthy and atopic dogs. Vet Dermatol 2010; 21: 112-117.
46. Rodrigues CA, Batista LF, Teixeira MC et al. Peripheral blood mononuclear cell supernatants from asymptomatic dogs immunized and experimentally challenged with Leishmania chagasi can stimulate canine macrophages to reduce infection in vitro. Vet Parasitol 2007; 143: 197-205.
47. Lee J, Hwang H, Jung E et al. Promotion of stem cell proliferation by vegetable peptone. Cell Prolif 2009; 42: 595-601.
48. Zhao Y, Yang J, Gao YD et al. Th17 immunity in patients with allergic asthma. Int Arch Allergy Immunol 2009; 151: 297-307.
49. Abbas AK, Lichtman AH, Pillai S. Cytokines. In: Schmitt W, Gruliow R, eds. Cellular and Molecular Immunology. Philadelphia: WB Saunders Co, 2010; 267-301.
50. Kim CK, Kim SW, Park CS et al. Bronchoalveolar lavage cytokine profiles in acute asthma and acute bronchiolitis. J Allergy Clin Immunol 2003; 112: 64-71.
51. Fonseca DE, Kline JN. Use of CpG oligonucleotides in treatment of asthma and allergic disease. Adv Drug Deliv Rev 2009; 61: 256-262.
52. Pasare C, Medzhitov R. Toll-like receptors: balancing host resistance with immune tolerance. Curr Opin Immunol 2003; 15: 677-682.
53. Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol 2008; 8: 523-532.
54. Gabrysova L, Nicolson KS, Streeter HB et al. Negative feedback control of the autoimmune response through antigen-induced differentiation of IL-10-secreting Th1 cells. J Exp Med 2009; 206: 1755-1767.
55. Hawrylowicz CM, O'Garra A. Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma. Nat Rev Immunol 2005; 5: 271-283.
56. O'Neill S, Drobatz K, Satyaraj E et al. Evaluation of cytokines and hormones in dogs before and after treatment of diabetic ketoacidosis and in uncomplicated diabetes mellitus. Vet Immunol Immunopathol 2012; 4: 276-283.